Publication

Economic evaluation of pneumococcal conjugate vaccination in The Gambia

Authored by:

Kim, S., Lee, G. and Goldie, S.

Full Citation:

Kim, S., Lee, G. and Goldie, S. 2010. Economic evaluation of pneumococcal conjugate vaccination in The Gambia. BMC Infectious Diseases. 10(260).

View Publication

Additional key concepts from this publication:

Vaccines are among the most cost-effective health interventions available.

Key Evidence: Assuming 90% coverage, a 9-valent PCV (PCV9) program in The Gambia would prevent approximately 630 hospitalizations, 40 deaths, and 1000 DALYs, for the birth cohort over the first 5 years of life. The estimated cost would be $670 per DALY averted in The Gambia.

Herd effects multiply the benefits of immunization.

Key Evidence: Assuming 90% coverage, a program in The Gambia using a 9-valent PCV (PCV9) would prevent approximately 630 hospitalizations, 40 deaths, and 1000 DALYs over the first 5 years of life of a birth cohort. The estimated cost would be $670 per DALY averted in The Gambia.